Trials / NCT02065011
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
Underway, not enrolling Phase 2 Drug / neuroprotection
- Sponsor
- Sanofi
- Treatment
- Blood draw for the laboratory assessment
- Gene
- Not stated
- Conditions
- Usher's Syndrome
- Ages
- 18 Years to no upper limit
- Enrollment
- 9 participants
- Started
- 2013-09-12
- Main results expected
- 2031-06-13
- Results posted
- Not yet
- Record last updated
- 2026-01-13
What the study is testing
Primary Objective:
To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B
Secondary Objective:
To assess long-term safety and biological activity of SAR421869
Where it runs
France (1)
- Investigational Site Number : 250001, Paris
United States (1)
- Oregon Health and Science University Site Number : 840001, Portland, Oregon